Jian-Sheng Kang

Dr. Jian-Sheng Kang

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2019 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
PLPei-Pei Liu
Pei-Pei Liu
YXYi Xie
Yi Xie
XMXiao-Yan Meng
Xiao-Yan Meng
JKJian-Sheng Kang
Jian-Sheng Kang
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients. There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis. However, the ultimate etiology of AD remains obscure. In this review, we discuss the main hypotheses of AD and related clinical trials. Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD. The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD. We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD.

1 January 2008 in Cell
Verified
Journal Article
Closed access
JKJian-Sheng Kang
Jian-Sheng Kang
JTJin-Hua Tian
Jin-Hua Tian
PPPing-Yue Pan
Ping-Yue Pan
PZPhilip Zald
Philip Zald
CLCuiling Li
Cuiling Li
ZSZu-Hang Sheng
Zu-Hang Sheng

29 June 2005 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
NWNathan R. Wilson
Nathan R. Wilson
JKJian-Sheng Kang
Jian-Sheng Kang
EHEmily V. Hueske
Emily V. Hueske
TLTony Leung
Tony Leung
HVHelene Varoqui
Helene Varoqui
GLGuosong Liu
Guosong Liu
A fundamental question in synaptic physiology is whether the unitary strength of a synapse can be regulated by presynaptic characteristics and, if so, what those characteristics might be. Here, we characterize a newly proposed mechanism for altering the strength of glutamatergic synapses based on the recently identified vesicular glutamate transporter VGLUT1. We provide direct evidence that filling in isolated synaptic vesicles is subject to a dynamic equilibrium that is determined by both the concentration of available glutamate and the number of vesicular transporters participating in loading. We observe that changing the number of vesicular transporters expressed at hippocampal excitatory synapses results in enhanced evoked and miniature responses and verify biophysically that these changes correspond to an increase in the amount of glutamate released per vesicle into the synaptic cleft. In addition, we find that this modulation of synaptic strength by vesicular transporter expression is endogenously regulated, both across development to coincide with a maturational increase in vesicle cycling and quantal amplitude and by excitatory and inhibitory receptor activation in mature neurons to provide an activity-dependent scaling of quantal size via a presynaptic mechanism. Together, these findings underscore that vesicular transporter expression is used endogenously to directly regulate the extent of glutamate release, providing a concise presynaptic mechanism for controlling the quantal efficacy of excitatory transmission during synaptic refinement and plasticity.

22 July 2019 in Nature Cell Biology
Verified
Journal Article
Closed access
LSLulu Sun
Lulu Sun
YWYuqing Wang
Yuqing Wang
JCJin Cen
Jin Cen
XMXiaolong Ma
Xiaolong Ma
LCLei Cui
Lei Cui
LHLijian Hui
Lijian Hui

14 March 2020 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
JKJian-Sheng Kang
Jian-Sheng Kang
Biosyntheses of proteins, nucleotides and fatty acids, are essential for the malignant proliferation and survival of cancer cells. Cumulating research findings show that amino acid restrictions are potential strategies for cancer interventions. Meanwhile, dietary strategies are popular among cancer patients. However, there is still lacking solid rationale to clarify what is the best strategy, why and how it is. Here, integrated analyses and comprehensive summaries for the abundances, signalling and functions of amino acids in proteomes, metabolism, immunity and food compositions, suggest that, intermittent dietary lysine restriction with normal maize as an intermittent staple food for days or weeks, might have the value and potential for cancer prevention or therapy. Moreover, dietary supplements were also discussed for cancer cachexia including dietary immunomodulatory.

11 January 2021 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
XWXin Wang
Xin Wang
LZLuyang Zhang
Luyang Zhang
WSWenxian Sun
Wenxian Sun
LPLu-Lu Pei
Lu-Lu Pei
MTMengke Tian
Mengke Tian
BSBo Song
Bo Song
Existing techniques have many limitations in the diagnosis and classification of ischemic stroke (IS). Considering this, we used metabolomics to screen for potential biomarkers of IS and its subtypes and to explore the underlying related pathophysiological mechanisms. Serum samples from 99 patients with acute ischemic stroke (AIS) [the AIS subtypes included 49 patients with large artery atherosclerosis (LAA) and 50 patients with small artery occlusion (SAO)] and 50 matched healthy controls (HCs) were analyzed by non-targeted metabolomics based on liquid chromatography–mass spectrometry. A multivariate statistical analysis was performed to identify potential biomarkers. There were 18 significantly different metabolites, such as oleic acid, linoleic acid, arachidonic acid, L-glutamine, L-arginine, and L-proline, between patients with AIS and HCs. These different metabolites are closely related to many metabolic pathways, such as fatty acid metabolism and amino acid metabolism. There were also differences in metabolic profiling between the LAA and SAO groups. There were eight different metabolites, including L-pipecolic acid, 1-Methylhistidine, PE, LysoPE, and LysoPC, which affected glycerophospholipid metabolism, glycosylphosphatidylinositol-anchor biosynthesis, histidine metabolism, and lysine degradation. Our study effectively identified the metabolic profiles of IS and its subtypes. The different metabolites between LAA and SAO may be potential biomarkers in the context of clinical diagnosis. These results highlight the potential of metabolomics to reveal new pathways for IS subtypes and provide a new avenue to explore the pathophysiological mechanisms underlying IS and its subtypes.